Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 295

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 295
---
’s software will become an integral
part of the tests developed by DiamiR.

DiamiR also plans on seeking trademark protection
for commercially valuable products it develops. At the date of this prospectus U.S. Federal trademark registrations for the marks CogniMIR
and DiamiR have been issued by the USPTO.

Market Size and Competition

US market opportunity for CogniMIR ®in selection of early-stage patients for clinical trials – the following key market statistics are relevant for assessment of
the overall size of this opportunity are compiled by the Alzheimer’s Association (alz.org):

<div align='center'>155</div>

| ● | The population of Americans age 65 and older is projected to grow from 58 million in 2021 to 88 million by 2050.                                                                                                                                                      |
| ● | The percentage of people with Alzheimer’s dementia increases with age: from 5.1% of people age 65 to 74 up to 33.4% of people age                                                                                                                                     
 85 and older have Alzheimer’s dementia.                                                                                                                                                                                                                               |
| ● | Almost 2/3 of American with AD are women. Of the 6.7 million people age 65 and older with Alzheimer’s dementia in the United States, 4.1 million are women and 2.6 million are men. This represents 12% of women and 9% of men age 65 and older in the United States. |
| ● | By 2025, the number of people age 65 and older with Alzheimer’s dementia is projected to reach 7.2 million — an 11% increase from the 6.7 million age 65 and older affected in 2023.                                                                                  |

| ● | The figures in the table above only reflect information pertaining to the United States.                                                                                                                    |
| ● | By 2060, the number of people age 65 and older with Alzheimer’s dementia is projected to reach 13.8 million, barring the development of medical breakthroughs to prevent, slow or cure Alzheimer’s disease. |
| ● | 240+ clinical trials on MCI / AD are currently ongoing in the US; average number of patients: 220 per trial (source: clinicaltrials.gov);                                                                   |

| ○ | The total number of patients screened                                                           
 per trial is at least the number of patients enrolled and frequently two to five times greater. |

Broad screening of population in high-risk groups(e.g. for AD registries) presents